The nomination of Heidi Overton to lead the FDA was withdrawn by the White House due to concerns about her support in the Senate. A pro-life group, Susan B. Anthony Pro-Life America, opposed her nomination, demanding commitments from the Trump administration regarding abortion drug policies. They are particularly focused on ending mail-order access to abortion drugs and calling for a new safety study on mifepristone, which they claim is flawed. The FDA's ongoing review of mifepristone is expected to conclude in December 2026.
Key facts
- Heidi Overton's FDA nomination was withdrawn by the White House this week.
- The pro-life group seeks to end mail-order access to abortion drugs.
- The FDA's safety review of mifepristone is ongoing, with results due in December 2026.
- Erik Baptist criticized the current safety study as flawed.
- Senator Bill Cassidy believed Overton could have been confirmed.
A short AI summary in our own words. The reporting belongs to Fox News — Latest; we don't reproduce it.